News

FDA vs EMA: The Camizestrant Controversy

FDA · oncology · 2 min

Astellas Faces Xtandi Patent Cliff: Strategic Moves Ahead

3 min

FDA's New Form 483 Response Guidance: Implications for Pharma

FDA · 3 min

Liminatus Pharma to Merge with InnocsAI: A Market Analysis

3 min

FDA Drug Approval Decisions Expected in May 2026: What to Anticipate

FDA · 3 min

BioMarin's SWOT Analysis: Competitive Challenges Ahead

rare disease · 4 min

Krystal Biotech Q1 Earnings Beat: Catalysts Ahead for 2026 & 2027

3 min

FDA Approves 17 Drugs with Continuous Manufacturing: Implications for Pharma

FDA · 2 min

RFK Jr.’s Muddled Claims on Drug Approval Speed in Oncology

oncology · 3 min

Best Cancer Stocks for 2026: Investment Insights

oncology · 3 min

FDA in Flux: May 2026 Drug Approvals Update

FDA · 2 min

Aptar Pharma Advances FDA-Funded Research Contract for Drug Approvals

FDA · 2 min